A major congressional effort to spur medical innovation passed another milestone today when a House of Representatives committee signed off on the 21st Century Cures Act.
The bill, developed by representatives Fred Upton (R–MI) and Diana DeGette (D–CO), revamps policies and provides new funding for the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). Approved unanimously by the House Energy and Commerce Committee, the bill contains a few changes from a version introduced in April.
As before, the measure authorizes annual $1.5 billion raises to NIH’s budget for 3 years and also provides $10 billion over 5 years in mandatory funding for a new NIH Innovation Fund. Annually, at least $500 million of the fund will support the new Accelerating Advancement Program, which would provide matching funds for NIH’s 27 institutes and centers for research in areas including biomarkers, precision medicine, infectious diseases, antibiotics, and basic research. The remainder would go to young scientists (at least 35%); high-risk, high-reward research; and NIH intramural research. This is somewhat different from an April draft bill that would have directed the Innovation Fund to young scientists, precision medicine, and a third, unnamed category.